Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Debt to Equity (2020 - 2022)

Historic Debt to Equity for Anika Therapeutics (ANIK) over the last 7 years, with Q2 2022 value amounting to $0.02.

  • Anika Therapeutics' Debt to Equity fell 7436.39% to $0.02 in Q2 2022 from the same period last year, while for Jun 2022 it was $0.02, marking a year-over-year decrease of 7436.39%. This contributed to the annual value of $0.02 for FY2021, which is 6872.21% down from last year.
  • Latest data reveals that Anika Therapeutics reported Debt to Equity of $0.02 as of Q2 2022, which was down 7436.39% from $0.02 recorded in Q1 2022.
  • In the past 5 years, Anika Therapeutics' Debt to Equity ranged from a high of $0.17 in Q2 2020 and a low of $0.01 during Q3 2021
  • Its 3-year average for Debt to Equity is $0.06, with a median of $0.05 in 2020.
  • Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 6606.71% in 2021, then tumbled by 8323.55% in 2022.
  • Anika Therapeutics' Debt to Equity (Quarter) stood at $0.05 in 2020, then plummeted by 68.72% to $0.02 in 2021, then rose by 0.33% to $0.02 in 2022.
  • Its Debt to Equity stands at $0.02 for Q2 2022, versus $0.02 for Q1 2022 and $0.02 for Q4 2021.